Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?

Intuitive Surgical shares are down roughly 29% year to date as da Vinci procedure growth slowed to 15% in the latest quarter from 17% in Q4 2025, with full-year growth guided to 13.5%-15.5%. Headwinds include a high-single-digit decline in U.S. bariatric cases tied to GLP-1 use, expired ACA subsidies, and intensifying robotic-surgery competition. Nonetheless, 24 of 32 surveyed analysts rate the stock buy/strong buy, with an average target implying 18% upside and a large long-term runway across roughly 9 million currently addressable and 20 million potential annual robotic procedures.

Analysis

ISRG’s valuation reset is only investable if procedure growth stabilizes near the low end of guidance without a corresponding reduction in system placements or recurring-instrument utilization. The key distinction is mix: GLP-1-driven weakness in bariatric surgery may be structurally durable, but bariatrics is not the core determinant of the installed-base flywheel. A broader deceleration in general surgery, urology, gynecology, or Ion utilization would imply lower lifetime system economics and justify further multiple compression.

The competitive risk is likely more consequential in international capital placements than near-term U.S. utilization. JNJ and MDT can subsidize placements, bundle broader hospital contracts, and tolerate lower robotics margins to gain installed-base access; ISRG’s defense is its surgeon training ecosystem and instrument revenue density. China is the most plausible source of downside surprise over 6-18 months because local competitors can pressure tender pricing before they meaningfully displace procedure volumes.

Consensus targets are a weak catalyst because they largely extrapolate historical recovery patterns rather than resolve whether the growth algorithm has changed. The nearer catalyst is the next two quarterly disclosures: U.S. procedure growth ex-bariatrics, international placement growth, and management’s ability to maintain procedure guidance. A reacceleration toward mid-teens growth could restore the premium multiple over 1-3 months; a cut below the current growth range would likely expose another 15-20% downside as investors re-underwrite recurring-revenue growth.

Contrarian view: the selloff may be directionally rational but too indiscriminate. GLP-1 adoption reduces a subset of surgical demand while potentially improving patients’ surgical eligibility and lowering complication rates elsewhere; the net effect is not yet observable. The cleaner relative expression is not a blanket short of rivals, whose robotics investments remain too immaterial to move consolidated earnings, but selective ISRG exposure sized around confirmation of utilization trends.

Key Decisions for Investors

• Maintain ISRG on a staged-buy watchlist rather than chase the drawdown: initiate one-third only after the next reported U.S. da Vinci procedure growth excluding bariatrics is at least 14% and full-year guidance is reaffirmed; add after evidence of stable system placement demand. Thesis invalidates on a guidance cut below 13.5% or two consecutive quarters of declining placement growth.
• For existing ISRG exposure, buy 3-6 month downside protection around the next earnings date rather than exit outright. The asymmetric event risk is a utilization/guidance miss, while a simple in-line quarter may not immediately reverse the de-rating.
• Monitor JNJ and MDT robotics disclosures as competitive leading indicators, not direct long substitutes. Escalate the ISRG competitive-risk case if either reports material U.S. placements, accelerating procedure utilization, or explicit tender wins in China; absent those data, competition remains strategically important but financially unproven.
• Track hospital ACA enrollment commentary and elective-procedure indicators over the next 1-3 months. Broad-based payer pressure would weaken the entire robotic-procedure growth assumption and favor reducing medtech utilization exposure, whereas stabilization would isolate the issue to bariatric mix.